Whitehawk Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing precision therapies for genetically-defined cancers. The company (WHWK)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Whitehawk Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing precision therapies for genetically-defined cancers. The company (WHWK) trades at $4.19 with AI Score 43/100 (Grade C). Whitehawk Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing precision therapies for genetically-defined cancers. Market cap: $207.21M, Sector: Healthcare.
Price live · AI analysis from May 9, 2026WHWK stock analysis for 2026: Analysts have set a consensus price target of $6.00 for Whitehawk Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing precision therapies for genetically-defined cancers. The company, suggesting 43.2% upside from the current price of $4.19. The AI MoonshotScore is 43/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
WHWK: 3/7 perspectives are bullish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Whitehawk Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing precision therapies for genetically-defined cancers. The company (WHWK) Healthcare & Pipeline Overview
Whitehawk Therapeutics Inc specializes in precision therapies for genetically-defined cancers, positioning itself as a forward-thinking player in the biotechnology sector with a focus on innovative treatment solutions tailored to individual patient needs.
What Is the Investment Thesis for WHWK?
Whitehawk Therapeutics Inc presents a unique investment thesis driven by its focus on precision therapies for genetically-defined cancers. With a market capitalization of $207.21M, the company is positioned in a rapidly expanding market, as the global precision medicine market is projected to reach $217 billion by 2028, growing at a CAGR of 10.6%. Key growth catalysts include successful clinical trial outcomes, potential partnerships with larger pharmaceutical companies, and advancements in genomic research that could enhance their therapeutic offerings. Additionally, the company's low beta of 0.62 indicates lower volatility compared to the broader market, which may appeal to risk-averse investors. However, risks such as regulatory hurdles, competition from established biotech firms, and the inherent uncertainties of clinical trials must be carefully considered. Overall, Whitehawk's innovative approach and strategic positioning within the biotechnology sector present a compelling case for potential growth.
Based on FMP financials and quantitative analysis
WHWK Key Highlights
- Market capitalization of $207.21M reflects a focused investment in precision oncology.
- The company operates in a rapidly growing precision medicine market projected to reach $217 billion by 2028.
- Whitehawk's low beta of 0.62 indicates lower volatility compared to the overall market.
- The company's clinical-stage pipeline is aimed at addressing unmet medical needs in oncology.
- No dividend yield as the company reinvests earnings into research and development.
Who Are WHWK's Competitors?
WHWK is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMGN Amgen Inc. | $366.92 | +0.13% | $198.03B | 82 |
| BMY Bristol-Myers Squibb Company | $57.97 | +2.23% | $118.37B | 88 |
| GILD Gilead Sciences, Inc. | $136.36 | +5.21% | 170B | 94 |
| NVS Novartis AG | $156.80 | +0.84% | $299.19B | 57 |
| REGN Regeneron Pharmaceuticals, Inc. | $672.47 | +3.49% | $69.28B | 91 |
| ANAB AnaptysBio, Inc. | $67.29 | +8.00% | $2.90B | 79 |
| SNDX Syndax Pharmaceuticals, Inc. | $23.12 | +4.69% | $2.05B | 79 |
| ABCL AbCellera Biologics Inc. | $7.69 | -2.29% | $2.35B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are WHWK's Key Strengths?
- Focused expertise in precision therapies for genetically-defined cancers.
- Innovative research capabilities leveraging genomic technologies.
- Strong leadership with experience in the biotechnology sector.
- Commitment to addressing unmet medical needs in oncology.
What Are WHWK's Weaknesses?
- Limited financial resources compared to larger competitors.
- Clinical-stage status may lead to higher risk and volatility.
- Dependence on successful outcomes from clinical trials.
- Small workforce may limit operational capacity.
What Could Drive WHWK Stock Higher?
- Results from ongoing clinical trials expected in Q4 2026, which could validate the efficacy of Whitehawk's precision therapies.
- Development of strategic partnerships with larger pharmaceutical companies to enhance research and commercialization efforts.
- Anticipated regulatory submissions for new therapies in 2026, which could lead to expedited approvals.
- Continuous advancements in genomic research that may support the development of innovative treatment options.
What Are the Key Risks for WHWK?
- Negative return on equity (-79.6%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles that could delay the approval of new therapies.
- Competition from established biotechnology firms with more resources.
- Market volatility affecting funding and investment opportunities.
- Dependence on successful outcomes from clinical trials, which carry inherent risks.
What Are the Growth Opportunities for WHWK?
- Growth opportunity 1: The global precision medicine market is projected to reach $217 billion by 2028, growing at a CAGR of 10.6%. Whitehawk Therapeutics can leverage this trend by advancing its clinical pipeline and focusing on therapies that address specific genetic mutations in cancer patients, potentially capturing significant market share as demand for personalized treatments increases.
- Growth opportunity 2: Collaborations with larger pharmaceutical companies can enhance Whitehawk's research capabilities and accelerate drug development timelines. By forming strategic partnerships, the company could gain access to additional resources, expertise, and distribution channels, which may lead to faster market entry for its therapies.
- Growth opportunity 3: The increasing prevalence of cancer globally, with an estimated 19.3 million new cases in 2020, underscores the urgent need for innovative treatment options. Whitehawk's focus on genetically-defined cancers positions it to address this growing demand, particularly as more patients seek targeted therapies that align with their genetic profiles.
- Growth opportunity 4: Advances in genomic technologies and personalized medicine are creating new avenues for drug discovery and development. Whitehawk can capitalize on these technological advancements to enhance its research capabilities, potentially leading to the development of novel therapies that meet the specific needs of cancer patients.
- Growth opportunity 5: Regulatory support for precision medicine initiatives is increasing, with agencies like the FDA providing pathways for expedited approvals of innovative therapies. Whitehawk Therapeutics can benefit from these supportive regulatory environments, which may facilitate faster access to the market for its precision therapies.
What Opportunities Does WHWK Have?
- Growing demand for personalized medicine in cancer treatment.
- Potential for strategic partnerships to enhance research and development.
- Increasing prevalence of cancer worldwide creates market opportunities.
- Advancements in genomic technologies can drive innovation.
What Threats Does WHWK Face?
- Intense competition from established biotechnology firms.
- Regulatory hurdles that may delay product approvals.
- Market volatility affecting funding and investment opportunities.
- Rapidly changing healthcare policies impacting drug pricing and access.
What Are WHWK's Competitive Advantages?
- Strong focus on precision medicine differentiates Whitehawk from traditional oncology companies.
- Innovative research capabilities in genomic technologies provide a competitive edge.
- Commitment to addressing unmet medical needs enhances market positioning.
- Strategic partnerships can bolster development and commercialization efforts.
What Does WHWK Do?
Founded with the mission to revolutionize cancer treatment, Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company headquartered in Pacific Palisades, California. The company is dedicated to developing precision therapies aimed at genetically-defined cancers, a growing field within the biotechnology industry that seeks to tailor treatments based on the genetic makeup of individual tumors. With a lean workforce of 40 employees, Whitehawk Therapeutics is positioned to rapidly innovate and adapt in a competitive landscape. The company's approach involves leveraging advanced genomic technologies and research to identify specific genetic targets in cancer cells, enabling the development of therapies that can potentially improve treatment efficacy and patient outcomes. As the biotechnology sector continues to evolve, Whitehawk Therapeutics aims to establish itself as a leader in precision medicine, focusing on unmet medical needs within oncology. The company is actively engaged in clinical trials to validate its therapies, contributing to the broader movement towards personalized medicine in cancer treatment. Whitehawk's commitment to innovation and patient-centric solutions is expected to drive its growth as it navigates the complexities of drug development and regulatory approval processes.
What Products and Services Does WHWK Offer?
- Develop precision therapies for genetically-defined cancers.
- Conduct clinical trials to validate the efficacy of their treatments.
- Utilize advanced genomic technologies to identify cancer-specific targets.
- Focus on personalized medicine to improve patient outcomes.
- Engage in research partnerships to enhance drug development.
- Aim to address unmet medical needs in oncology.
How Does WHWK Make Money?
- Generate revenue through the development and commercialization of targeted cancer therapies.
- Engage in partnerships and collaborations with larger pharmaceutical companies.
- Leverage funding from grants and investments to support research and development.
- Focus on clinical trials to bring innovative therapies to market.
What Industry Does WHWK Operate In?
The biotechnology industry is characterized by rapid innovation and a strong focus on developing targeted therapies, particularly in oncology. The global precision medicine market is expected to grow significantly, driven by advancements in genomic research and increasing demand for personalized treatment options. Whitehawk Therapeutics Inc operates within this dynamic landscape, competing against established firms and emerging biotech companies. The shift towards precision therapies is reshaping cancer treatment paradigms, with an emphasis on developing drugs that target specific genetic mutations, thereby improving treatment efficacy and patient outcomes. As the industry evolves, companies like Whitehawk are well-positioned to capitalize on these trends.
Who Are WHWK's Key Customers?
- Oncology healthcare providers seeking innovative treatment options.
- Patients diagnosed with genetically-defined cancers.
- Pharmaceutical partners interested in collaboration for drug development.
- Research institutions focusing on cancer genomics.
How Whitehawk Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing precision therapies for genetically-defined cancers. The company Is Valued
Whitehawk Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing precision therapies for genetically-defined cancers. The company carries a market capitalization of $207.21M, placing it in the micro-cap category. Relative to its peer group, WHWK's quantitative score of 43/100 is below the peer average of 82/100.
Company Profile
Whitehawk Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing precision therapies for genetically-defined cancers. The company operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Pacific Palisades, US. The company is led by CEO David J. Lennon. WHWK has traded publicly since 2017.
ROE -80%Key Financial Metrics
Return on equity for Whitehawk Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing precision therapies for genetically-defined cancers. The company stands at -79.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -91.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -47.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 11.36 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -39.9%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 1/9Financial Health
Whitehawk Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing precision therapies for genetically-defined cancers. The company's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 4.73 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Whitehawk Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing precision therapies for genetically-defined cancers. The company revenue of about $8.8M for fiscal 2026, with EPS near $-1.28. The estimate reflects 6 contributing analysts.
WHWK Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Whitehawk's focus on genetically-defined cancers aligns with the growing trend of personalized medicine, potentially attracting investor interest.
- Positive community sentiment indicates growing awareness and optimism around Whitehawk's approach to cancer treatment.
- Insider activity suggests confidence in the company's direction and potential future success.
- The biopharmaceutical sector is experiencing renewed interest, driven by advancements in precision medicine and targeted therapies.
Bear Case
- Clinical-stage biopharmaceutical companies face inherent risks related to drug development and regulatory approvals.
- Negative community sentiment could signal concerns about the company's progress or competitive landscape.
- Market perception of Whitehawk may be influenced by broader economic uncertainties affecting the biotech industry.
- The company's success is heavily dependent on the outcome of clinical trials, which are subject to unforeseen challenges and delays.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
WHWK Latest News
-
12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga · May 13, 2026
-
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga · May 13, 2026
WHWK Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for WHWK.
Price Targets
Consensus target: $6.00
WHWK MoonshotScore
What does this score mean?
The MoonshotScore rates WHWK's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: David J. Lennon
Chief Executive Officer
David J. Lennon has a robust background in the biotechnology sector, with extensive experience in leading clinical-stage companies. He holds advanced degrees in life sciences and has held various leadership roles in both startup and established firms. His expertise spans drug development, strategic planning, and operational management, contributing to his effective leadership at Whitehawk Therapeutics.
Track Record: Under David's leadership, Whitehawk Therapeutics has made significant strides in advancing its clinical pipeline and establishing partnerships that enhance its research capabilities. His strategic decisions have focused on innovation and addressing unmet medical needs in oncology, positioning the company for potential growth.
Whitehawk Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing precision therapies for genetically-defined cancers. The company Healthcare Stock: Key Questions Answered
What does Whitehawk Therapeutics Inc do?
Whitehawk Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing precision therapies for genetically-defined cancers. The company leverages advanced genomic technologies to identify specific genetic targets in cancer cells, aiming to create tailored treatments that improve patient outcomes and address unmet medical needs in oncology.
What do analysts say about WHWK stock?
Analyst consensus on WHWK stock reflects a cautious outlook, emphasizing the importance of successful clinical trial outcomes and regulatory approvals. Key valuation metrics indicate that the company is in a high-risk stage due to its clinical focus, but the potential for significant growth exists if its therapies demonstrate efficacy in trials.
What are the main risks for WHWK?
Whitehawk Therapeutics faces several risks, including regulatory hurdles that may delay product approvals and competition from larger, established biotechnology firms. Additionally, the company's reliance on successful clinical trial outcomes poses a risk, as any setbacks could significantly impact its market position and financial stability.
What are the key factors to evaluate for WHWK?
Whitehawk Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing precision therapies for genetically-defined cancers. The company (WHWK) holds an AI score of 43/100 (low). Analysts target $6.00 (+43%). Not financial advice.
How frequently does WHWK data refresh on this page?
WHWK prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven WHWK's recent stock price performance?
Whitehawk Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing precision therapies for genetically-defined cancers. The company (WHWK) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focused expertise in precision therapies for genetically-defined cancers. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider WHWK overvalued or undervalued right now?
Valuing Whitehawk Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing precision therapies for genetically-defined cancers. The company (WHWK) requires multiple metrics. Analysts target $6.00 (+43%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying WHWK?
Before investing in Whitehawk Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing precision therapies for genetically-defined cancers. The company (WHWK), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The information provided is based on available data as of May 2026 and may be subject to change.